Literature DB >> 26126163

Fecal immunochemical testing results and characteristics of colonic lesions.

Sascha C van Doorn1, Inge Stegeman2, An K Stroobants3, Marco W Mundt4, Thomas R de Wijkerslooth1, Paul Fockens1, Ernst J Kuipers5, Patrick M Bossuyt2, Evelien Dekker1.   

Abstract

BACKGROUND AND STUDY AIMS: Fecal immunochemical tests (FIT) are used to detect blood in feces, which might indicate the presence of colorectal neoplasia. The aim of this study was to investigate whether FIT results vary depending on the characteristics of colonic lesions. PATIENTS AND METHODS: This was a retrospective analysis of lesions detected in a cohort of asymptomatic individuals (aged 50 - 75 years) who were invited to participate in a FIT-based screening pilot in The Netherlands. The mean FIT result was compared across subgroups of individuals defined by histopathology of the most advanced lesion detected. In addition, the results were compared with data from a primary colonoscopy screening trial, in which participants also completed a FIT.
RESULTS: In three rounds of FIT-based screening, a total of 877 FIT-positive individuals underwent colonoscopy. Higher mean FIT results (hemoglobin [Hb]/g feces) were observed in individuals with carcinomas (199 μg Hb/g) and advanced adenomas (87 μg Hb/g) compared with participants with nonadvanced adenomas (50 μg Hb/g) or those with serrated lesions (46 μg Hb/g) (P < 0.001). In the primary colonoscopy trial, 1256 participants completed a FIT test and underwent colonoscopy. The number of participants with nonadvanced adenomas as the most advanced lesion was comparable between this group and the FIT-based screening group (20 % vs. 22 %).
CONCLUSION: In FIT-based screening, the mean FIT results varied depending on the characteristics of the most advanced colonic lesion. The proportion of participants with a nonadvanced adenoma as the most advanced lesion was similar in the FIT-based screening group and in the primary colonoscopy screening group, suggesting that these lesions are coincidental findings rather than FIT-detected findings. CLINICAL TRIAL REGISTRATION: www.trialregister.nl number NTR2755. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 26126163     DOI: 10.1055/s-0034-1392412

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  11 in total

Review 1.  Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.

Authors:  Esmée J Grobbee; Pieter Ha Wisse; Eline H Schreuders; Aafke van Roon; Leonie van Dam; Ann G Zauber; Iris Lansdorp-Vogelaar; Wichor Bramer; Sarah Berhane; Jonathan J Deeks; Ewout W Steyerberg; Monique E van Leerdam; Manon Cw Spaander; Ernst J Kuipers
Journal:  Cochrane Database Syst Rev       Date:  2022-06-06

2.  Detection of serrated lesions in proximal colon by simulated sigmoidoscopy vs faecal immunochemical testing in a multicentre, pragmatic, randomised controlled trial.

Authors:  Laura Carot; Antoni Castells; Cristina Hernández; Cristina Alvarez-Urturi; Francesc Balaguer; Angel Lanas; Joaquín Cubiella; Jose D Tasende; Rodrigo Jover; Vicent Hernandez; Fernando Carballo; Luis Bujanda; Enrique Quintero; Montserrat Andreu; Xavier Bessa
Journal:  United European Gastroenterol J       Date:  2018-09-26       Impact factor: 4.623

3.  Cancer-associated fecal microbial markers in colorectal cancer detection.

Authors:  Vincy Eklöf; Anna Löfgren-Burström; Carl Zingmark; Sofia Edin; Pär Larsson; Pontus Karling; Oleg Alexeyev; Jörgen Rutegård; Maria L Wikberg; Richard Palmqvist
Journal:  Int J Cancer       Date:  2017-09-06       Impact factor: 7.396

4.  Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies.

Authors:  Xiao-Ming Sun; Yuan-Hong Xie; Qin-Yan Gao; Guo-Xiang Cai; Tian-Hui Zou; Hui-Min Chen; Si-Yi Yu; Yi-Wen Qiu; Wei-Qi Gu; Xiao-Yu Chen; Yun Cui; Danfeng Sun; Zhan-Ju Liu; San-Jun Cai; Jie Xu; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  EBioMedicine       Date:  2017-10-04       Impact factor: 8.143

5.  Quantile-based fecal hemoglobin concentration for assessing colorectal neoplasms with 1,263,717 Taiwanese screenees.

Authors:  Szu-Min Peng; Han-Mo Chiu; Hsiao-Hsuan Jen; Chen-Yang Hsu; Sam Li-Sheng Chen; Sherry Yueh-Hsia Chiu; Amy Ming-Fang Yen; Jean Ching-Yuan Fann; Yi-Chia Lee; Hsiu-Hsi Chen
Journal:  BMC Med Inform Decis Mak       Date:  2019-05-02       Impact factor: 2.796

6.  Feasibility and performance of the fecal immunochemical test (FIT) for average-risk colorectal cancer screening in Nigeria.

Authors:  Gregory C Knapp; Olusegun Alatise; Bolatito Olopade; Marguerite Samson; Olalekan Olasehinde; Funmilola Wuraola; Oluwole O Odujoko; Akinwunmi O Komolafe; Olujide O Arije; Philip E Castle; J Joshua Smith; Martin R Weiser; T Peter Kingham
Journal:  PLoS One       Date:  2021-01-12       Impact factor: 3.240

7.  A prospective study of faecal immunochemical testing following polypectomy in a colorectal cancer screening population.

Authors:  David J Gibson; Blathnaid Nolan; Joanna Rea; Maire Buckley; Gareth Horgan; Kieran Sheahan; Glen A Doherty; Diarmuid O'Donoghue; Hugh E Mulcahy; Alan Smith; Garret Cullen
Journal:  Frontline Gastroenterol       Date:  2017-11-04

8.  Advances in Fecal Tests for Colorectal Cancer Screening.

Authors:  Eline H Schreuders; Esmée J Grobbee; Manon C W Spaander; Ernst J Kuipers
Journal:  Curr Treat Options Gastroenterol       Date:  2016-03

9.  First steps towards combining faecal immunochemical testing with the gut microbiome in colorectal cancer screening.

Authors:  Esmée J Grobbee; Suk Yee Lam; Gwenny M Fuhler; Blerdi Blakaj; Sergey R Konstantinov; Marco J Bruno; Maikel P Peppelenbosch; Ernst J Kuipers; Manon Cw Spaander
Journal:  United European Gastroenterol J       Date:  2019-12-19       Impact factor: 4.623

Review 10.  Novel Diagnostic Biomarkers in Colorectal Cancer.

Authors:  Aneta L Zygulska; Piotr Pierzchalski
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.